Vical Incorporated (Nasdaq: VICL) declared a investigate cooperation with the Karolinska Institute, a directive dweller scrutiny university, and the Nordic Institute for Infectious Disease Control (SMI), a governmental proficient agency, to appraise Vical’s Vaxfectin(R) adjuvant with the Biojector(R) 2000 needle-free shot grouping (Bioject Medical Technologies Inc., OTCBB:BJCT) for a ambiguous clogging polymer immunogen against HIV. Professor Eric Sandstrom, M.

Tags: Dna, Europe, Hiv, Research Co, Technologies Inc